# Turning heterogeneity of statistical epistasis networks to an advantage

**Authors:** Diane Duroux, Federico Melograna, Héctor Climente-González, Bowen Fan, Andrew Walakira, Edoardo Efrem Gervasoni, Zuqi Li, Damian Roqueiro, Fabio Stella, Kristel Van Steen

PMC · DOI: 10.1093/bib/bbaf699 · 2026-01-19

## TL;DR

This paper introduces a workflow to manage inconsistencies in genetic interaction studies, turning diverse results into useful insights for biomedical research.

## Contribution

A novel workflow is introduced to characterize and leverage heterogeneity in GWAIS results using Statistical Epistasis Networks.

## Key findings

- Comparing SNP-pair rankings and SENs helps identify clusters of protocols with similar outcomes.
- SENs enable visualization of epistasis detection variation and prioritize recurrent interactions.
- Aggregating SENs can enhance the utility of GWAIS for understanding disease genetics.

## Abstract

Epistasis detection is hindered by multiple challenges, including the proliferation of analytic tools and the diverse methodological choices made in Genome-Wide Association Interaction Studies (GWAIS). These factors often produce inconsistent and only partially overlapping results, with individual methods emphasizing distinct aspects of epistasis. Although comparative evaluations of GWAIS approaches exist, they generally do not identify the factors responsible for methodological discrepancies or assess their implications for biomedical research. Consequently, it remains unclear which features of GWAIS strategies contribute most to these differences and which methods are most appropriate for revealing specific genetic architectures. Here, we present a workflow designed to characterize heterogeneity in GWAIS results and derive practical recommendations systematically. First, we assess non-replicability by comparing single nucleotide polymorphisms-pair rankings and Statistical Epistasis Networks (SENs)—graphs in which nodes represent genetic loci and edges denote epistatic interactions—to identify clusters of protocols with similar outcomes. SENs provide a structured framework for visualizing and comparing variation in epistasis detection, enabling prioritization of interactions recurrently identified across methods. Second, we propose strategies to reduce heterogeneity and enhance robustness, with particular emphasis on interpretability. Notably, we demonstrate that differences among SENs can be informative rather than disadvantageous, as they yield complementary perspectives on disease genetics. Finally, we highlight the benefits of informed SEN aggregation, showing how this approach can strengthen the utility of GWAIS for elucidating biological mechanisms relevant to disease prevention, diagnosis, and management.

## Full-text entities

- **Genes:** TLR5 (toll like receptor 5) [NCBI Gene 7100] {aka MELIOS, SLE1, SLEB1, TIL3}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NPSR1 (neuropeptide S receptor 1) [NCBI Gene 387129] {aka ASRT2, FNSS3, GPR154, GPRA, NPSR, PGR14}, PDZK1 (PDZ domain containing 1) [NCBI Gene 5174] {aka CAP70, CLAMP, NHERF-3, NHERF3, PDZD1}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, LEPR (leptin receptor) [NCBI Gene 3953] {aka CD295, LEP-R, LEPRD, OB-R, OBR, huB219}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, LNPEP (leucyl and cystinyl aminopeptidase) [NCBI Gene 4012] {aka CAP, IRAP, P-LAP, PLAP}, SNORA63 (small nucleolar RNA, H/ACA box 63) [NCBI Gene 6043] {aka E3, E3-2, RNE3, RNU107, SNORA63A, elF-4AII}, ZBTB46 (zinc finger and BTB domain containing 46) [NCBI Gene 140685] {aka BTBD4, BZEL, RINZF, ZNF340, dJ583P15.7, dJ583P15.8}, ERAP1 (endoplasmic reticulum aminopeptidase 1) [NCBI Gene 51752] {aka A-LAP, ALAP, APPILS, ARTS-1, ARTS1, ERAAP}, SLC22A5 (solute carrier family 22 member 5) [NCBI Gene 6584] {aka CDSP, OCTN2}, NOD2 (nucleotide binding oligomerization domain containing 2) [NCBI Gene 64127] {aka ACUG, BLAU, BLAUS, CARD15, CD, CLR16.3}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, SLC22A4 (solute carrier family 22 member 4) [NCBI Gene 6583] {aka DFNB60, ETTh, OCTN1}, HLA-F (major histocompatibility complex, class I, F) [NCBI Gene 3134] {aka CDA12, HLA-5.4, HLA-CDA12, HLAF}
- **Diseases:** SEN (MESH:C536623), mucosal injury (MESH:D052016), obesity (MESH:D009765), IBD (MESH:D015212), bladder cancer (MESH:D001749), UC (MESH:D003093), bowel inflammations (MESH:D007249), asthma (MESH:D001249), CD (MESH:D003424), GWAIS (MESH:D042822), cancer (MESH:D009369)
- **Chemicals:** CASMAP (-), Nitrogen (MESH:D009584)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs932826, rs10489136, rs16837624, rs7431710, rs4653522, rs1876839, rs4858795, rs17130482, rs2066844, rs5743293, rs10492963, rs4809335

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12814973/full.md

---
Source: https://tomesphere.com/paper/PMC12814973